ATE460164T1 - Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure - Google Patents

Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure

Info

Publication number
ATE460164T1
ATE460164T1 AT05710692T AT05710692T ATE460164T1 AT E460164 T1 ATE460164 T1 AT E460164T1 AT 05710692 T AT05710692 T AT 05710692T AT 05710692 T AT05710692 T AT 05710692T AT E460164 T1 ATE460164 T1 AT E460164T1
Authority
AT
Austria
Prior art keywords
pitavastatins
agent
treating hyperlipidemia
eicosapentaenic acid
acid
Prior art date
Application number
AT05710692T
Other languages
English (en)
Inventor
Taro Aoki
Junji Yamaguchi
Yusuke Sasaki
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Application granted granted Critical
Publication of ATE460164T1 publication Critical patent/ATE460164T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05710692T 2004-02-19 2005-02-18 Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure ATE460164T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/780,640 US7022713B2 (en) 2004-02-19 2004-02-19 Hyperlipemia therapeutic agent
PCT/JP2005/003092 WO2005079797A2 (en) 2004-02-19 2005-02-18 Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid

Publications (1)

Publication Number Publication Date
ATE460164T1 true ATE460164T1 (de) 2010-03-15

Family

ID=34860884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05710692T ATE460164T1 (de) 2004-02-19 2005-02-18 Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure

Country Status (14)

Country Link
US (2) US7022713B2 (de)
EP (1) EP1715865B9 (de)
JP (1) JP5474276B2 (de)
KR (1) KR101376449B1 (de)
CN (1) CN100475208C (de)
AT (1) ATE460164T1 (de)
CY (1) CY1110133T1 (de)
DE (1) DE602005019856D1 (de)
DK (1) DK1715865T3 (de)
ES (1) ES2342609T3 (de)
PL (1) PL1715865T3 (de)
PT (1) PT1715865E (de)
SI (1) SI1715865T1 (de)
WO (1) WO2005079797A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1614429A4 (de) * 2003-04-17 2007-05-02 Kowa Co Lklf/klf2 gen-expressionspromoter
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
JP5069448B2 (ja) * 2006-02-07 2012-11-07 持田製薬株式会社 脳卒中再発予防用組成物
WO2007091338A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 脳卒中再発予防用組成物
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US7728697B2 (en) * 2006-09-26 2010-06-01 Mg Materials Corporation Systems and methods for electrically reducing ferroelectric materials to increase bulk conductivity
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
US20100119600A1 (en) * 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
KR20110039249A (ko) * 2008-07-07 2011-04-15 모치다 세이야쿠 가부시키가이샤 지질 이상증의 개선 또는 치료약
EP3187182B1 (de) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon
RU2505292C2 (ru) 2009-02-10 2014-01-27 Амарин Фармасьютикалз Айрлэнд Лимитед Способы лечения гипертриглицеридемии
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
ES2661812T3 (es) * 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Composiciones
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (de) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Zusammensetzungen und verfahren zur senkung der konzentration an hochsensitivem c-reaktiven protein (hs-crp) bei einer person
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
ES2826201T3 (es) 2013-10-30 2021-05-17 Patheon Softgels Inc Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2015200563A1 (en) * 2014-06-26 2015-12-30 Banner Life Sciences Llc Enhanced bioavailability of polysaturated fatty acids
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
WO2016026139A1 (zh) * 2014-08-22 2016-02-25 财团法人国防教育研究基金会 用于治疗非酒精性脂肪肝疾病的药物及应用
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
AU731692C (en) * 1996-10-11 2001-10-11 Scarista Limited Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1370544A (zh) * 2001-02-27 2002-09-25 张洪超 一种具有降血脂作用的林蛙卵油营养保健胶囊及其制法
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
CA2450820C (en) * 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
CN1197564C (zh) * 2001-09-30 2005-04-20 中国药品生物制品检定所 海狗油在制备治疗脂代谢紊乱药物中的应用
CA2496831A1 (en) * 2002-08-26 2004-03-04 Lipid Sciences, Inc. Treating alzheimers using delipidated protein particles
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent

Also Published As

Publication number Publication date
JP2007523049A (ja) 2007-08-16
US7022713B2 (en) 2006-04-04
HK1098953A1 (zh) 2007-08-03
CN1921860A (zh) 2007-02-28
US20060111437A1 (en) 2006-05-25
PL1715865T3 (pl) 2010-09-30
WO2005079797A3 (en) 2006-05-11
US7776881B2 (en) 2010-08-17
EP1715865B1 (de) 2010-03-10
EP1715865A2 (de) 2006-11-02
KR20060109988A (ko) 2006-10-23
ES2342609T3 (es) 2010-07-09
DE602005019856D1 (de) 2010-04-22
CN100475208C (zh) 2009-04-08
EP1715865B8 (de) 2010-05-19
DK1715865T3 (da) 2010-05-10
US20050187292A1 (en) 2005-08-25
SI1715865T1 (sl) 2010-08-31
CY1110133T1 (el) 2015-01-14
JP5474276B2 (ja) 2014-04-16
KR101376449B1 (ko) 2014-03-19
WO2005079797A2 (en) 2005-09-01
EP1715865B9 (de) 2010-12-15
PT1715865E (pt) 2010-04-01

Similar Documents

Publication Publication Date Title
DE602005019856D1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
DE602005019319D1 (de) Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
EP1622608A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE602007004615D1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
DE602004010708D1 (de) Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
EP3351211C0 (de) Sklerale prothese zur behandlung von altersweitsichtigkeit und anderen augenerkrankungen
EA200970529A1 (ru) Антивирусная композиция и способ ее применения
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
WO2008027880A3 (en) Strontium-based treatment of otosclerosis
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
ATE445644T1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
EP2023725A4 (de) Pestizidzusammensetzungen zur behandlung von gliederfüssern und verwendungsverfahren dafür
WO2006083667A8 (en) Treatment of oxygen induced inflammatory tissue injury

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1715865

Country of ref document: EP